high mobility group box 2 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored HMGB2P1 profile across patient tissues and cancer cell-line models. HMGB2P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HMGB2P1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, HMGB2P1 RNA expression shows 13,924 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, and ESCA as cancer lineages where HMGB2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB2P1 survival associations across molecular data types. HMGB2P1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB2P1 RNA expression–survival associations across cancer types. High HMGB2P1 expression shows unfavorable associations in KIRC, LIHC, KIRP and MESO, but favorable associations in CESC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HMGB2P1 RNA expression.
This table summarizes HMGB2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB2P1 shows higher tumor expression in KIRC, LUAD, HNSC, COAD, LIHC and KICH. The KIRC box plot shows higher HMGB2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.223, t-test p < 0.001).
This table shows molecular features associated with HMGB2P1 in patient tissues and cancer cell lines. In patient samples, HMGB2P1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
